Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: A dose comparison study

Anat Galor, Carol Karp, S. Chhabra, S. Barnes, Eduardo C Alfonso

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Background/aims: To compare the effectiveness and side-effect profile of two doses of interferon alpha2b (IFNa2b) eye-drops (1 million international units (IU)/ml versus 3 million IU/ml) in the treatment of ocular surface squamous neoplasia (OSSN). Methods: Retrospective case series. Results: Thirty-five eyes were identified over an 11-year period (1996-2007). Twenty-one eyes (19 patients) with conjunctival intraepithelial neoplasia (CIN) were treated with 1 million IU/ml of topical IFN-α2b; 12 eyes (nine patients) with CIN were treated with 3 million IU/ml. Two patients with squamous cell carcinoma (SCC) were treated with topical interferon, one with 1 million IU/ml and one with 3 million IU/ml. Baseline demographic information was not statistically different between the two groups. In patients with CIN, topical therapy eliminated disease in 81% of eyes in the 1 million IU/ml group versus 92%, in the 3 million IU/ml group, p=0.41. The median time to OSSN resolution was 2.8 months in the 1 million IU/ml group and 1.9 months in the 3 million IU/ml group, p=0.55. Neither eye with SCC responded to interferon therapy. Topical therapy was well tolerated. After a median follow-up of 24 months, three recurrences were seen in eyes successfully treated with topical therapy. Conclusion: In our study, there were no significant differences between the 1 million IU/ml group and the 3 million IU/ml group for the treatment of CIN.

Original languageEnglish
Pages (from-to)551-554
Number of pages4
JournalBritish Journal of Ophthalmology
Volume94
Issue number5
DOIs
StatePublished - May 18 2010

Fingerprint

interferon alfa-2b
Ophthalmic Solutions
Neoplasms
Interferons
Therapeutics
Squamous Cell Carcinoma

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

@article{5e45d68c7538498c979b48614e7a33d5,
title = "Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: A dose comparison study",
abstract = "Background/aims: To compare the effectiveness and side-effect profile of two doses of interferon alpha2b (IFNa2b) eye-drops (1 million international units (IU)/ml versus 3 million IU/ml) in the treatment of ocular surface squamous neoplasia (OSSN). Methods: Retrospective case series. Results: Thirty-five eyes were identified over an 11-year period (1996-2007). Twenty-one eyes (19 patients) with conjunctival intraepithelial neoplasia (CIN) were treated with 1 million IU/ml of topical IFN-α2b; 12 eyes (nine patients) with CIN were treated with 3 million IU/ml. Two patients with squamous cell carcinoma (SCC) were treated with topical interferon, one with 1 million IU/ml and one with 3 million IU/ml. Baseline demographic information was not statistically different between the two groups. In patients with CIN, topical therapy eliminated disease in 81{\%} of eyes in the 1 million IU/ml group versus 92{\%}, in the 3 million IU/ml group, p=0.41. The median time to OSSN resolution was 2.8 months in the 1 million IU/ml group and 1.9 months in the 3 million IU/ml group, p=0.55. Neither eye with SCC responded to interferon therapy. Topical therapy was well tolerated. After a median follow-up of 24 months, three recurrences were seen in eyes successfully treated with topical therapy. Conclusion: In our study, there were no significant differences between the 1 million IU/ml group and the 3 million IU/ml group for the treatment of CIN.",
author = "Anat Galor and Carol Karp and S. Chhabra and S. Barnes and Alfonso, {Eduardo C}",
year = "2010",
month = "5",
day = "18",
doi = "10.1136/bjo.2008.153197",
language = "English",
volume = "94",
pages = "551--554",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia

T2 - A dose comparison study

AU - Galor, Anat

AU - Karp, Carol

AU - Chhabra, S.

AU - Barnes, S.

AU - Alfonso, Eduardo C

PY - 2010/5/18

Y1 - 2010/5/18

N2 - Background/aims: To compare the effectiveness and side-effect profile of two doses of interferon alpha2b (IFNa2b) eye-drops (1 million international units (IU)/ml versus 3 million IU/ml) in the treatment of ocular surface squamous neoplasia (OSSN). Methods: Retrospective case series. Results: Thirty-five eyes were identified over an 11-year period (1996-2007). Twenty-one eyes (19 patients) with conjunctival intraepithelial neoplasia (CIN) were treated with 1 million IU/ml of topical IFN-α2b; 12 eyes (nine patients) with CIN were treated with 3 million IU/ml. Two patients with squamous cell carcinoma (SCC) were treated with topical interferon, one with 1 million IU/ml and one with 3 million IU/ml. Baseline demographic information was not statistically different between the two groups. In patients with CIN, topical therapy eliminated disease in 81% of eyes in the 1 million IU/ml group versus 92%, in the 3 million IU/ml group, p=0.41. The median time to OSSN resolution was 2.8 months in the 1 million IU/ml group and 1.9 months in the 3 million IU/ml group, p=0.55. Neither eye with SCC responded to interferon therapy. Topical therapy was well tolerated. After a median follow-up of 24 months, three recurrences were seen in eyes successfully treated with topical therapy. Conclusion: In our study, there were no significant differences between the 1 million IU/ml group and the 3 million IU/ml group for the treatment of CIN.

AB - Background/aims: To compare the effectiveness and side-effect profile of two doses of interferon alpha2b (IFNa2b) eye-drops (1 million international units (IU)/ml versus 3 million IU/ml) in the treatment of ocular surface squamous neoplasia (OSSN). Methods: Retrospective case series. Results: Thirty-five eyes were identified over an 11-year period (1996-2007). Twenty-one eyes (19 patients) with conjunctival intraepithelial neoplasia (CIN) were treated with 1 million IU/ml of topical IFN-α2b; 12 eyes (nine patients) with CIN were treated with 3 million IU/ml. Two patients with squamous cell carcinoma (SCC) were treated with topical interferon, one with 1 million IU/ml and one with 3 million IU/ml. Baseline demographic information was not statistically different between the two groups. In patients with CIN, topical therapy eliminated disease in 81% of eyes in the 1 million IU/ml group versus 92%, in the 3 million IU/ml group, p=0.41. The median time to OSSN resolution was 2.8 months in the 1 million IU/ml group and 1.9 months in the 3 million IU/ml group, p=0.55. Neither eye with SCC responded to interferon therapy. Topical therapy was well tolerated. After a median follow-up of 24 months, three recurrences were seen in eyes successfully treated with topical therapy. Conclusion: In our study, there were no significant differences between the 1 million IU/ml group and the 3 million IU/ml group for the treatment of CIN.

UR - http://www.scopus.com/inward/record.url?scp=77952215937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952215937&partnerID=8YFLogxK

U2 - 10.1136/bjo.2008.153197

DO - 10.1136/bjo.2008.153197

M3 - Article

C2 - 19493859

AN - SCOPUS:77952215937

VL - 94

SP - 551

EP - 554

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 5

ER -